562 related articles for article (PubMed ID: 29875318)
1. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
2. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
4. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
[TBL] [Abstract][Full Text] [Related]
5. Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review.
Whyte MP; Deepak Amalnath S; McAlister WH; Pedapati R; Muthupillai V; Duan S; Huskey M; Bijanki VN; Mumm S
Bone; 2018 Nov; 116():321-332. PubMed ID: 30077757
[TBL] [Abstract][Full Text] [Related]
6. Anti-sclerostin - is there an indication?
Larsson S
Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
[TBL] [Abstract][Full Text] [Related]
7. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
8. Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization.
Lewis KJ; Choi RB; Pemberton EZ; Bullock WA; Firulli AB; Robling AG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505764
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
[TBL] [Abstract][Full Text] [Related]
10. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
[TBL] [Abstract][Full Text] [Related]
11. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
13. Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice.
Choi RB; Hoggatt AM; Horan DJ; Rogers EZ; Loots GG; Robling AG
J Bone Miner Res; 2023 May; 38(5):765-774. PubMed ID: 36891756
[TBL] [Abstract][Full Text] [Related]
14. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
[TBL] [Abstract][Full Text] [Related]
15. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin: therapeutic horizons based upon its actions.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
[TBL] [Abstract][Full Text] [Related]
18. The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.
Boudin E; Yorgan T; Fijalkowski I; Sonntag S; Steenackers E; Hendrickx G; Peeters S; De Maré A; Vervaet B; Verhulst A; Mortier G; D'Haese P; Schinke T; Van Hul W
J Bone Miner Res; 2017 Aug; 32(8):1739-1749. PubMed ID: 28477420
[TBL] [Abstract][Full Text] [Related]
19. Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice.
Yang H; Büttner A; Albiol L; Julien C; Thiele T; Figge C; Kramer I; Kneissel M; Duda GN; Checa S; Willie BM
Sci Rep; 2020 Dec; 10(1):22299. PubMed ID: 33339872
[TBL] [Abstract][Full Text] [Related]
20. Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton.
Choi RB; Hoggatt AM; Horan DJ; Rogers EZ; Hong JM; Robling AG
Aging Dis; 2022 Dec; 13(6):1891-1900. PubMed ID: 36465166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
